[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Raz Design Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":97},{"warningLetters":4,"total":96},[5,33,54,77],{"id":6,"raw":7,"subject":12,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":28,"issuing_office":11,"recipient_name":29,"body_fetched_at":30,"delivery_method":31,"recipient_title":20,"reference_number":20,"action_taken_date":32,"medical_device_id":20,"response_letter_date":20},401,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2025-12-18T16:00:00Z\">12\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-16T05:00:00Z\">12\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarli-washington-design-llc-720840-12162025\">Marli Washington Design, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Failure to Register and List\u002FMisbranded","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarli-washington-design-llc-720840-03272026\">\u003Ctime datetime=\"2026-04-02T04:00:00Z\">04\u002F02\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marli Washington\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marli Washington Design, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2502 Harford Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Baltimore\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21218\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:legal@gc2b.info\"> legal@gc2b.info\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS #720840\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>December 16, 2025\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Marli Washington:\u003Cbr>\u003Cbr>The United States Food and Drug Administration (FDA) has reviewed Marli Washington Design, LLC d\u002Fb\u002Fa gc2b’s (“your firm”) website (gc2b.co) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Our review of your firm’s website revealed statements that these breast binders (example trade names: “Black Half Binder (Classic 2.0)”, “Black Tank Binder (Classic 2.0)”, “White Half Binder (Classic 2.0)”, “White Tank Binder (Classic 2.0)”, “Nude No. 5 Half Binder (Classic 2.0)”, “2b Luxe White Racerback”, “2b Luxe Black Half”) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:\u003C\u002Fp>\u003Cp>•&nbsp;&nbsp;&nbsp;&nbsp;Per your firm’s website: “our product is aimed at helping to relieve dysphoria for trans folks”\u003C\u002Fp>\u003Cp>Our review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. § 360) (e.g., “Our founder, CEO, and designer . . . .”; “Using his background in Industrial Design and expertise in textiles . . . .”; “The result was the first binder designed and patented specifically for gender-affirming chest binding.”). Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. &nbsp;In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. &nbsp;Our records indicate that you have not registered or listed these devices for fiscal year 2026.\u003C\u002Fp>\u003Cp>Therefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. &nbsp;Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure and injunction. &nbsp;\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.&nbsp;\u003Cbr>\u003Cbr>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS 720840” when replying.&nbsp;\u003Cbr>\u003Cbr>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance. &nbsp; &nbsp;\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002Fs\u002F\u003Cbr>Michael J. Hoffmann\u003Cbr>Director\u003Cbr>Office of Health Technology 3 - Gastrorenal, ObGyn,\u003Cbr>General Hospital, and Urology Devices\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003Cbr>Food and Drug Administration\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>Spotify, Inc.: abuse@spotify.com, abuse@gc2b.co, support@gc2b.co\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMarli Washington\n\nRecipient Title\n\nManager\n\nMarli Washington Design, LLC\n\n2502 Harford Rd\n\nBaltimore, MD 21218\n\nUnited States\n\nlegal@gc2b.info\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nCMS #720840\n\nDecember 16, 2025\n\nDear Marli Washington:\n\nThe United States Food and Drug Administration (FDA) has reviewed Marli Washington Design, LLC d\u002Fb\u002Fa gc2b’s (“your firm”) website (gc2b.co) and observed that your website offers various breast binders for sale. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nOur review of your firm’s website revealed statements that these breast binders (example trade names: “Black Half Binder (Classic 2.0)”, “Black Tank Binder (Classic 2.0)”, “White Half Binder (Classic 2.0)”, “White Tank Binder (Classic 2.0)”, “Nude No. 5 Half Binder (Classic 2.0)”, “2b Luxe White Racerback”, “2b Luxe Black Half”) are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body, including:\n• Per your firm’s website: “our product is aimed at helping to relieve dysphoria for trans folks”\nOur review also revealed statements that you manufacture these devices within the meaning of section 510 of the Act (21 U.S.C. § 360) (e.g., “Our founder, CEO, and designer . . . .”; “Using his background in Industrial Design and expertise in textiles . . . .”; “The result was the first binder designed and patented specifically for gender-affirming chest binding.”). Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year. Our records indicate that you have not registered or listed these devices for fiscal year 2026.\nTherefore the devices are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that they were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure and injunction.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS 720840” when replying.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002Fs\u002F\nMichael J. Hoffmann\nDirector\nOffice of Health Technology 3 - Gastrorenal, ObGyn,\nGeneral Hospital, and Urology Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nFood and Drug Administration\n\nSpotify, Inc.: abuse@spotify.com, abuse@gc2b.co, support@gc2b.co","Marli Washington Design, LLC","marli-washington-design-llc-720840-12162025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarli-washington-design-llc-720840-12162025","2026-10-26T08:09:20.803778+00:00","Warning Letter","Closed Out","2025-12-18","720840","Medical Devices","2026-04-02","Marli Washington","2026-08-19T07:21:05.364+00:00","VIA Electronic Mail","2025-12-16",{"id":34,"raw":35,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":19,"fei_number":20,"letter_url":44,"updated_at":45,"action_type":23,"case_status":46,"posted_date":32,"marcs_cms_no":47,"product_type":48,"closeout_date":20,"issuing_office":38,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":20,"reference_number":52,"action_taken_date":53,"medical_device_id":20,"response_letter_date":20},420,[9,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2025-12-04T05:00:00Z\">12\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F3d-imaging-drug-design-and-development-llc-716213-12042025\">3D Imaging Drug Design and Development LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FPositron Emission Tomography (PET) Drugs\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-23\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marc S. Berridge, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>3D Imaging Drug Design and Development LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9015 Carti Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Little Rock\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-23\u003C\u002Fp>\u003Cp>December 4, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Berridge:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, 3D Imaging Drug Design and Development LLC, FEI 3009143510, at 9015 Carti Way, Little Rock, from June 9 to 13, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that you failed to update the listing for your PET human prescription drug product, Fludeoxyglucose F18 (NDC 76451-118), as required under section 510(j) of the FD&amp;C Act (21 U.S.C. 360(j)) and 21 CFR part 207.\u003C\u002Fp>\u003Cp>Thus, Fludeoxyglucose F18 is not properly listed, and your firm has not fulfilled its listing obligations under 510(j) of the FD&amp;C Act (21 U.S.C. 360(j)) and 21 CFR 207, which is prohibited under section 301(p) of the FD&amp;C Act (21 U.S.C. 331(p)). This violation is described in more detail below.\u003C\u002Fp>\u003Cp>We reviewed your June 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your facilities are not adequate to ensure the prevention of contamination of equipment or product by substances, personnel, or environmental conditions that could reasonably be expected to have an adverse effect on product quality. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed (21 CFR 212.30(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Facility Suitability\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to ensure that your facility is adequately designed and controlled to prevent contamination of the sterile injectable PET drugs you manufacture. For example, our investigator observed your operator making aseptic connections in an open benchtop area, without adequate aseptic environmental conditions. Furthermore, our investigator observed that Hot Cell #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is used to manufacture Fludeoxyglucose F-18 (FDG), was in a poor state of repair, with rust on the manipulator arms and with visible residue on surfaces near where the finished product is filtered into sterile vials.\u003C\u002Fp>\u003Cp>In your response, you state that you made facility and equipment repairs, including removal of rust and replacement of the chipped lead shielding in your hot cell. Your response is inadequate because you do not evaluate your facility, process, and equipment for potential routes of contamination or address how you will improve your process to ensure that your product is properly protected from the environment during aseptic connections.\u003C\u002Fp>\u003Cp>Appropriate aseptic environments should be used for critical aseptic manipulation in the production and testing of PET drugs.\u003C\u002Fp>\u003Cp>\u003Cem>Environmental Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to establish and follow adequate testing procedures for environmental monitoring (EM) for your aseptic manufacturing area. For example, your Hot Cell #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, where the FDG drug product is filtered into the final product vials, is not monitored. Further, the alert and action levels that you established in your standard operating procedure (“SOP for Environmental Monitoring of Hot Cells”) for EM are not appropriate. For surface samples taken in your hot cell, your procedure does not require an investigation unless \u003Cstrong>(b)(4)\u003C\u002Fstrong> or more colony-forming units are recovered from a single sample. Your high action levels allow for an unacceptable risk of contamination to your product.\u003C\u002Fp>\u003Cp>In your response, you indicate that you lack an understanding of where the environmental monitoring should occur, and that you will update your EM to include a location “adjacent to the sterile closure.” Your response is inadequate because you do not address how you will determine the appropriate sampling location and frequency for EM.\u003C\u002Fp>\u003Cp>PET drug products have short expiry periods. Thus, your PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Therefore, adequate microbiological monitoring of the aseptic environment is essential during critical aseptic manipulation. A vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes but is not limited to:\u003Cbr>o All human interactions within the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your updated procedure(s) demonstrating that aseptic connections will be conducted in an appropriate environment (e.g., ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> aseptic workstation).\u003C\u002Fli>\u003Cli>An independent assessment of your EM program, including but not limited to establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis, and a comprehensive corrective action and preventive action plan.\u003C\u002Fli>\u003Cli>Your action levels for ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> surfaces, air, and operator gloves, and revised procedures that describe the appropriate response to contamination in critical environments.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to have adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality, and purity (21 CFR 212.50).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure that your operators are appropriately gowned to adequately protect the sterile injectable PET drugs you manufacture. For example, our investigator observed exposed skin and hair on your operator during the manufacturing of FDG lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The operators’ skin on their arms was exposed while they were setting up production in an open benchtop area of the room (i.e. with inadequate aseptic environmental conditions). The operators’ skin was also exposed while leaning into Hot Cell #\u003Cstrong>(b)(4)\u003C\u002Fstrong> to set up for product \u003Cstrong>(b)(4)\u003C\u002Fstrong> into sterile vials. Additionally, another operator was observed reaching into the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> laminar flow hood with exposed skin on the operator’s arms and face while performing sterility testing for FDG lots \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Furthermore, you failed to adequately requalify two of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> operators at least annually by conducting a media fill to assess their aseptic processing technique. For example, one of your operators had not been requalified to perform PET drug manufacturing using process simulations (media fills) since April 2021. However, the operator manufactured FDG as recently as June 2025.\u003C\u002Fp>\u003Cp>In your response, you indicate that the two operators were removed from production and a media fill was initiated. However, your response is inadequate because you do not provide a retrospective assessment of the potential impact to drug products manufactured from 2021 to present. Your response is also inadequate because you do not comprehensively address how you will ensure that your gowning program is adequate, including whether appropriate gowning will be used.\u003C\u002Fp>\u003Cp>Adequate gowning is an essential part of environmental control because gowns provide a barrier to prevent operators from contaminating the drug product. Personnel should be adequately trained and qualified to ensure their competence to perform aseptic processing of PET drugs.\u003C\u002Fp>\u003Cp>Media fills should simulate the aseptic production process, including but not limited to the aseptic assembly of the container\u002Fclosure system through filling of the PET drug into final containers. Operators should be requalified annually by conducting one media fill run. See FDA’s guidance document \u003Cem>Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F81974\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes but is not limited to evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your gowning program, including but not limited to how you will establish adequate gowning.\u003C\u002Fli>\u003Cli>The report and results for the media fill initiated on June 16, 2025, and any subsequent media fills conducted.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your media fill procedure, including but not limited to how you will ensure that operators are requalified annually.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to have laboratory methods suitable for their intended use and sufficiently sensitive, specific, accurate, and reproducible (21 CFR 212.60).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to establish and follow adequate testing procedures for sterility testing of your sterile injectable PET drugs. For example, our investigator observed your operator performing sterility testing using poor aseptic technique, including opening sterile components outside of the ISO \u003Cstrong>(b)(4)\u003C\u002Fstrong> laminar flow hood before use. Also, our investigator observed your chemist vigorously shaking the sterility test sample tubes before reading the results. Shaking the sterility test sample tubes may mask the test results and may impact a person’s ability to visually detect turbidity, visible colonies, or other evidence of microorganisms.\u003C\u002Fp>\u003Cp>In your response, you indicate that you updated your sterility testing procedure. However, your response is inadequate because it lacks information about how you will ensure that your procedures are sufficiently detailed for operators to follow and how you will ensure that sterility testing is adequately performed.\u003C\u002Fp>\u003Cp>Testing is a critical control that provides assurance that your PET drug products are sterile and therefore suitable for their intended use. It is important that you follow established, appropriate procedures to ensure that your sterility testing can detect the presence of microorganisms.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your sterility testing program, including but not limited to material flow and environmental monitoring.\u003C\u002Fli>\u003Cli>A comprehensive review of your sterility testing procedure relative to the expectations in the United States Pharmacopeia (USP) General Chapter &lt;71,&gt; Sterility Tests.\u003C\u002Fli>\u003Cli>Your most recent static and dynamic smoke studies performed for the laminar flow hood.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Drug Listing Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 510(j) of the FD&amp;C Act (21 U.S.C. 360(j)) and 21 CFR part 207 set forth the requirements for the listing of drugs. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2), registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1 through December 31 annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> You failed to update or certify Fludeoxyglucose F18 as required.\u003C\u002Fp>\u003Cp>Therefore, Fludeoxyglucose F18 is not properly listed under section 510(j) of the FD&amp;C Act. Failure to properly list a drug in accordance with 510(j) of the FD&amp;C Act is prohibited under section 301(p) of the FD&amp;C Act (21 U.S.C. 331(p)).\u003C\u002Fp>\u003Cp>Complete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply-chain security, and postmarket surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\u003Cp>In addition, we note that your drug listings for Ammonia N 13 (NDC 76451-013) and Sodium Fluoride F-18 (NDC 76451-018) also have not been updated or certified. Please update the listing information for these drugs to reflect their current status. If you no longer manufacture and distribute these drugs, then the drugs must be discontinued by adding an end marketing date. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding your drug listings, please contact us at eDRLS@fda.hhs.gov for further assistance.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&amp;C Act, 21 U.S.C. 360, 21 CFR part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at \u003Cem>Electronic Drug Registration and Listing Instructions\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>\u003Cstrong>Guidance on Positron Emission Tomography (PET) Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document, \u003Cem>PET Drugs—Current Good Manufacturing Practice\u003C\u002Fem>, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009143510 and ATTN: Lynnsey Renn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-23\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMarc S. Berridge, Ph.D.\n\nRecipient Title\n\nPresident\n\n3D Imaging Drug Design and Development LLC\n\n9015 Carti Way\n\nLittle Rock, AR 72205\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-23\nDecember 4, 2025\nDear Dr. Berridge:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, 3D Imaging Drug Design and Development LLC, FEI 3009143510, at 9015 Carti Way, Little Rock, from June 9 to 13, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for positron emission tomography (PET) drugs. See Title 21 Code of Federal Regulations (CFR), part 212 (21 CFR part 212).\nBecause your methods, facilities, or controls for manufacturing, processing, packaging, or holding do not conform to CGMP, your PET drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, we reviewed your firm’s drug listing submissions in FDA’s electronic Drug Registration and Listing System (eDRLS) and found that you failed to update the listing for your PET human prescription drug product, Fludeoxyglucose F18 (NDC 76451-118), as required under section 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207.\nThus, Fludeoxyglucose F18 is not properly listed, and your firm has not fulfilled its listing obligations under 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR 207, which is prohibited under section 301(p) of the FD&C Act (21 U.S.C. 331(p)). This violation is described in more detail below.\nWe reviewed your June 30, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your facilities are not adequate to ensure the prevention of contamination of equipment or product by substances, personnel, or environmental conditions that could reasonably be expected to have an adverse effect on product quality. Procedures to ensure that all equipment is clean, suitable for its intended purposes, properly installed, maintained, and capable of repeatedly producing valid results, are not adequately followed (21 CFR 212.30(a) and (b)).\nFacility Suitability\nYou failed to ensure that your facility is adequately designed and controlled to prevent contamination of the sterile injectable PET drugs you manufacture. For example, our investigator observed your operator making aseptic connections in an open benchtop area, without adequate aseptic environmental conditions. Furthermore, our investigator observed that Hot Cell #(b)(4), which is used to manufacture Fludeoxyglucose F-18 (FDG), was in a poor state of repair, with rust on the manipulator arms and with visible residue on surfaces near where the finished product is filtered into sterile vials.\nIn your response, you state that you made facility and equipment repairs, including removal of rust and replacement of the chipped lead shielding in your hot cell. Your response is inadequate because you do not evaluate your facility, process, and equipment for potential routes of contamination or address how you will improve your process to ensure that your product is properly protected from the environment during aseptic connections.\nAppropriate aseptic environments should be used for critical aseptic manipulation in the production and testing of PET drugs.\nEnvironmental Monitoring\nYou failed to establish and follow adequate testing procedures for environmental monitoring (EM) for your aseptic manufacturing area. For example, your Hot Cell #(b)(4), where the FDG drug product is filtered into the final product vials, is not monitored. Further, the alert and action levels that you established in your standard operating procedure (“SOP for Environmental Monitoring of Hot Cells”) for EM are not appropriate. For surface samples taken in your hot cell, your procedure does not require an investigation unless (b)(4) or more colony-forming units are recovered from a single sample. Your high action levels allow for an unacceptable risk of contamination to your product.\nIn your response, you indicate that you lack an understanding of where the environmental monitoring should occur, and that you will update your EM to include a location “adjacent to the sterile closure.” Your response is inadequate because you do not address how you will determine the appropriate sampling location and frequency for EM.\nPET drug products have short expiry periods. Thus, your PET drug products are released and administered before the results of batch specific sterility testing and EM are known. Therefore, adequate microbiological monitoring of the aseptic environment is essential during critical aseptic manipulation. A vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\nIn response to this letter, provide:\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes but is not limited to:\no All human interactions within the ISO (b)(4) area\no Equipment placement and ergonomics\no Air quality in the ISO (b)(4) area and surrounding room\no Facility layout\no Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour updated procedure(s) demonstrating that aseptic connections will be conducted in an appropriate environment (e.g., ISO (b)(4) aseptic workstation).\nAn independent assessment of your EM program, including but not limited to establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis, and a comprehensive corrective action and preventive action plan.\nYour action levels for ISO (b)(4) surfaces, air, and operator gloves, and revised procedures that describe the appropriate response to contamination in critical environments.\n2. Your firm failed to have adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality, and purity (21 CFR 212.50).\nYou failed to ensure that your operators are appropriately gowned to adequately protect the sterile injectable PET drugs you manufacture. For example, our investigator observed exposed skin and hair on your operator during the manufacturing of FDG lot (b)(4). The operators’ skin on their arms was exposed while they were setting up production in an open benchtop area of the room (i.e. with inadequate aseptic environmental conditions). The operators’ skin was also exposed while leaning into Hot Cell #(b)(4) to set up for product (b)(4) into sterile vials. Additionally, another operator was observed reaching into the ISO (b)(4) laminar flow hood with exposed skin on the operator’s arms and face while performing sterility testing for FDG lots (b)(4) and (b)(4).\nFurthermore, you failed to adequately requalify two of the (b)(4) operators at least annually by conducting a media fill to assess their aseptic processing technique. For example, one of your operators had not been requalified to perform PET drug manufacturing using process simulations (media fills) since April 2021. However, the operator manufactured FDG as recently as June 2025.\nIn your response, you indicate that the two operators were removed from production and a media fill was initiated. However, your response is inadequate because you do not provide a retrospective assessment of the potential impact to drug products manufactured from 2021 to present. Your response is also inadequate because you do not comprehensively address how you will ensure that your gowning program is adequate, including whether appropriate gowning will be used.\nAdequate gowning is an essential part of environmental control because gowns provide a barrier to prevent operators from contaminating the drug product. Personnel should be adequately trained and qualified to ensure their competence to perform aseptic processing of PET drugs.\nMedia fills should simulate the aseptic production process, including but not limited to the aseptic assembly of the container\u002Fclosure system through filling of the PET drug into final containers. Operators should be requalified annually by conducting one media fill run. See FDA’s guidance document Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F81974\u002Fdownload.\nIn response to this letter, provide:\nA remediation plan that better assures ongoing management oversight throughout the manufacturing lifecycle of all drug products. Provide a more data-driven and scientifically sound program that identifies sources of process variability and assures that manufacturing operations meet appropriate parameters and quality standards. This includes but is not limited to evaluating suitability of equipment for its intended use, ensuring quality of input materials, determining the capability and reliability of each manufacturing process step and its controls, and vigilant ongoing monitoring of process performance and product quality.\nA comprehensive assessment of your gowning program, including but not limited to how you will establish adequate gowning.\nThe report and results for the media fill initiated on June 16, 2025, and any subsequent media fills conducted.\nA comprehensive assessment of your media fill procedure, including but not limited to how you will ensure that operators are requalified annually.\n3. Your firm failed to have laboratory methods suitable for their intended use and sufficiently sensitive, specific, accurate, and reproducible (21 CFR 212.60).\nYou failed to establish and follow adequate testing procedures for sterility testing of your sterile injectable PET drugs. For example, our investigator observed your operator performing sterility testing using poor aseptic technique, including opening sterile components outside of the ISO (b)(4) laminar flow hood before use. Also, our investigator observed your chemist vigorously shaking the sterility test sample tubes before reading the results. Shaking the sterility test sample tubes may mask the test results and may impact a person’s ability to visually detect turbidity, visible colonies, or other evidence of microorganisms.\nIn your response, you indicate that you updated your sterility testing procedure. However, your response is inadequate because it lacks information about how you will ensure that your procedures are sufficiently detailed for operators to follow and how you will ensure that sterility testing is adequately performed.\nTesting is a critical control that provides assurance that your PET drug products are sterile and therefore suitable for their intended use. It is important that you follow established, appropriate procedures to ensure that your sterility testing can detect the presence of microorganisms.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive assessment of your sterility testing program, including but not limited to material flow and environmental monitoring.\nA comprehensive review of your sterility testing procedure relative to the expectations in the United States Pharmacopeia (USP) General Chapter \u003C71,> Sterility Tests.\nYour most recent static and dynamic smoke studies performed for the laminar flow hood.\nDrug Listing Violations\nSection 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207 set forth the requirements for the listing of drugs. Under 21 CFR 207.57(b), registrants are required to update drug listing information twice each year, in June and December. Under 21 CFR 207.57(b)(2), registrants may satisfy the listing update requirement with respect to unchanged listing information by making a single “no changes” certification during the October 1 through December 31 annual registration period. If the drug listing data is not updated or certified, the outdated listing data will get inactivated at the next scheduled FDA inactivation period.1 You failed to update or certify Fludeoxyglucose F18 as required.\nTherefore, Fludeoxyglucose F18 is not properly listed under section 510(j) of the FD&C Act. Failure to properly list a drug in accordance with 510(j) of the FD&C Act is prohibited under section 301(p) of the FD&C Act (21 U.S.C. 331(p)).\nComplete, accurate, and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs, including drug establishment inspections, supply-chain security, and postmarket surveillance. Establishment registration and drug listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\nIn addition, we note that your drug listings for Ammonia N 13 (NDC 76451-013) and Sodium Fluoride F-18 (NDC 76451-018) also have not been updated or certified. Please update the listing information for these drugs to reflect their current status. If you no longer manufacture and distribute these drugs, then the drugs must be discontinued by adding an end marketing date. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding your drug listings, please contact us at eDRLS@fda.hhs.gov for further assistance.\nIt is your responsibility to ensure that all drugs manufactured at your establishment comply with all establishment registration and drug listing requirements under section 510 of the FD&C Act, 21 U.S.C. 360, 21 CFR part 207, and all other applicable FDA regulations. Registration and listing information and instructions on how to properly register an establishment or submit drug listings can be found at Electronic Drug Registration and Listing Instructions.\nGuidance on Positron Emission Tomography (PET) Drugs\nSee FDA’s guidance document, PET Drugs—Current Good Manufacturing Practice, to help you meet the CGMP requirements when manufacturing PET drugs, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71013\u002Fdownload. This guidance document also references FDA’s guidance document, Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice for additional concepts and expectations that may apply to PET drug manufacturing, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to evaluate your operations to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009143510 and ATTN: Lynnsey Renn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 See 84 FR 40417 (https:\u002F\u002Fwww.regulations.gov\u002Fdocument\u002FFDA-2019-N-2374-0001).\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","3D Imaging Drug Design and Development LLC","3d-imaging-drug-design-and-development-llc-716213-12042025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F3d-imaging-drug-design-and-development-llc-716213-12042025","2026-10-26T08:07:47.726648+00:00","Issued","716213","Drugs","Marc S. Berridge, Ph.D.","2026-08-19T07:21:49.964+00:00","VIA UPS","320-26-23","2025-12-04",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":46,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":20,"issuing_office":60,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":20,"reference_number":75,"action_taken_date":76,"medical_device_id":20,"response_letter_date":20},1052,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2025-02-25T05:00:00Z\">02\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-21T05:00:00Z\">02\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Floveli-design-llc-dba-alice-vapeland-702516-02212025\">Loveli Design, LLC d\u002Fb\u002Fa Alice in Vapeland\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502253\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John Flynn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Loveli Design, LLC d\u002Fb\u002Fa Alice in Vapeland\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5740 Osuna Rd NE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Albuquerque\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nicole@aliceinvapeland.com\"> nicole@aliceinvapeland.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nicoleinvapeland@gmail.com\"> nicoleinvapeland@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:brandon@aliceinvapeland.com\"> brandon@aliceinvapeland.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:annette@aliceinvapeland.com\"> annette@aliceinvapeland.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hannah@aliceinvapeland.com\"> hannah@aliceinvapeland.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jahflynn@aliceinvapeland.com\"> jahflynn@aliceinvapeland.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 21, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear John Flynn:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Faliceextracts.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under Section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Unflavored Alice 60ml 6mg, Unflavored Alice 60ml 11mg, and Unflavored Alice 15ml 18mg.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under Section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under Section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under Section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by Section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of Section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502253, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003C\u002Fp>\u003Cp>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>Loveli Design, LLC\u003Cbr>Attn: John Flynn and Nicole Li\u003Cbr>6007 Osuna Rd N.E.\u003Cbr>Albuquerque, NM 87109\u003C\u002Fp>\u003Cp>Loveli Design, LLC\u003Cbr>8426 12th Ave\u003Cbr>Silver Spring, MD 20903\u003C\u002Fp>\u003Cp>Albuquerque Business Law, P.C.\u003Cbr>1801-B Rio Grande Blvd NW\u003Cbr>Albuquerque, NM 87104\u003C\u002Fp>\u003Cp>Squarespace Domains II LLC\u003Cbr>abuse-complaints@squarespace.com\u003C\u002Fp>\u003Cp>Google LLC\u003Cbr>google-cloud-compliance@google.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2502253\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJohn Flynn\n\nLoveli Design, LLC d\u002Fb\u002Fa Alice in Vapeland\n\n5740 Osuna Rd NE\n\nAlbuquerque, NM 87109\n\nUnited States\n\nnicole@aliceinvapeland.com\n\nnicoleinvapeland@gmail.com\n\nbrandon@aliceinvapeland.com\n\nannette@aliceinvapeland.com\n\nhannah@aliceinvapeland.com\n\njahflynn@aliceinvapeland.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nFebruary 21, 2025\nWARNING LETTER\nDear John Flynn:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Faliceextracts.com and determined that e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquids, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under Section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Unflavored Alice 60ml 6mg, Unflavored Alice 60ml 11mg, and Unflavored Alice 15ml 18mg.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under Section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under Section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under Section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by Section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of Section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502253, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA UPS and Electronic Mail\ncc:\nLoveli Design, LLC\nAttn: John Flynn and Nicole Li\n6007 Osuna Rd N.E.\nAlbuquerque, NM 87109\nLoveli Design, LLC\n8426 12th Ave\nSilver Spring, MD 20903\nAlbuquerque Business Law, P.C.\n1801-B Rio Grande Blvd NW\nAlbuquerque, NM 87104\nSquarespace Domains II LLC\nabuse-complaints@squarespace.com\nGoogle LLC\ngoogle-cloud-compliance@google.com","Loveli Design, LLC d\u002Fb\u002Fa Alice in Vapeland","loveli-design-llc-dba-alice-vapeland-702516-02212025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Floveli-design-llc-dba-alice-vapeland-702516-02212025","2026-10-26T08:09:16.472721+00:00","2025-02-25","702516","Tobacco","John Flynn","2026-08-19T17:00:53.905+00:00","VIA UPS and Electronic Mail","RW2502253","2025-02-21",{"id":78,"raw":79,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":66,"fei_number":20,"letter_url":88,"updated_at":89,"action_type":23,"case_status":46,"posted_date":90,"marcs_cms_no":91,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":20,"reference_number":20,"action_taken_date":95,"medical_device_id":20,"response_letter_date":20},1341,[80,81,82,11,83,13,13,13],"\u003Ctime datetime=\"2024-07-30T13:20:00Z\">07\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-06-25T04:00:00Z\">06\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famco-international-manufacturing-design-inc-681557-06252024\">AMCO International Manufacturing &amp; Design, Inc.\u003C\u002Fa>","Unapproved Device Violation","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Adam Milewski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AMCO International Manufacturing &amp; Design, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>410 Conselyea Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11211-2202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS # 681557\u003C\u002Fp>\n\n\u003Cp>June 25, 2024\u003Cbr>\n\u003Cbr>\nDear Adam Milewski:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 410 Conselyea Street, Brooklyn, NY on March 11, 2024, through March 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of replacement batteries (AMCO Part Numbers AM9146-2, AM5070, AM1000, 5L318, 6L785, 5L500, and AM9141) for use in Automated External Defibrillators (AEDs). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Devices and Radiological Health (“CDRH”) of the Food and Drug Administration (FDA) published a final order entitled “Effective Date of Requirement for Premarket Approval for Automated External Defibrillator Systems” in the Federal Register (80 FR 5674) effective on February 3, 2015. AED systems consist of an AED and those AED accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., pad electrodes, batteries, adapters, and hardware keys for pediatric use) (“necessary AED accessories”). The final order required the submission, by May 4, 2015, of a premarket approval (“PMA”) application for AEDs and necessary AED accessories that were in commercial distribution before May 28, 1976, or that were, by May 4, 2015, found to be substantially equivalent to any AED or necessary AED accessory that was in commercial distribution before May 28, 1976.\u003C\u002Fp>\n\n\u003Cp>At the time of the final order, FDA announced its intent not to enforce compliance with the 90 day deadline to submit a PMA for then currently marketed AEDs for 15 months after the deadline, provided certain qualifications were met. FDA also stated that it did not intend to enforce compliance with the PMA submission requirement for necessary AED accessories for 60 months following the February 3, 2015, effective date of the final order, which was February 3, 2020.\u003C\u002Fp>\n\n\u003Cp>On October 28, 2020, FDA issued the guidance document, “Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date,” to revise its compliance policy regarding the deadline for filing PMA applications for previously cleared necessary AED accessories. The purpose of this guidance was, in part, to present a less burdensome policy consistent with the public health given the challenges related to the Coronavirus Disease 2019 (COVID-19) pandemic. The guidance outlined that FDA did not intend to enforce compliance with the premarket approval requirements under section 515 of the Act for necessary AED accessories for AED systems, classified under 21 CFR 870.5310 and product codes MKJ and NSA, until February 3, 2022.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm manufactures batteries that are used with AED systems, specifically part number AM9146-2 intended to be used with the Cardiac Science Powerheart G3 and G3 Plus devices, part number AM5070 intended to be used with the Philips HeartStart FRx, OnSite, and Home devices, and part number AM1000 intended to be used with the Physio-Control LifePak 1000 device.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FDA has determined that your firm has not submitted a PMA by the February 3, 2022, compliance date for these devices and that your firm has continued to manufacture and distribute these devices after the compliance date.\u003C\u002Fp>\n\n\u003Cp>Consequently, your devices are adulterated under section 501(f)(1)(A) of the Act, 21 U.S.C. § 351(f)(1)(A), because they have been required by an order issued under section 515(b) of the Act, 21 U.S.C. § 360e(b), to have an approval under such section of an application for premarket approval, are not exempt from section 515 under section 520(g) of the Act, 21 U.S.C. § 360j(g), and your firm has not filed an application for premarket approval by the compliance date cited above.\u003C\u002Fp>\n\n\u003Cp>The kind of information that your firm needs to submit in order to obtain approval for the devices is available through the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether your products may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that your firm cease activities that result in the adulteration of necessary AED accessories.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 681557 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Joseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health Division 1\u003Cbr>\nORA Division Director\u003C\u002Fp>\n\n\u003Cp>and\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman\u003Cbr>\nDirector Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Our inspection also revealed that your firm has manufactured other batteries that are used with AED systems, including part number 5L318, 6L785, 5L500, and AM9141. These batteries are intended to be used with devices that have been discontinued. Your firm has continued to manufacture and distribute these devices after the February 3, 2022 compliance date.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAdam Milewski\n\nRecipient Title\n\nPresident\n\nAMCO International Manufacturing & Design, Inc.\n\n410 Conselyea Street\n\nBrooklyn, NY 11211-2202\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 681557\n\nJune 25, 2024\n\nDear Adam Milewski:\n\nDuring an inspection of your firm located at 410 Conselyea Street, Brooklyn, NY on March 11, 2024, through March 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of replacement batteries (AMCO Part Numbers AM9146-2, AM5070, AM1000, 5L318, 6L785, 5L500, and AM9141) for use in Automated External Defibrillators (AEDs). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nUnapproved Device Violation\n\nThe Center for Devices and Radiological Health (“CDRH”) of the Food and Drug Administration (FDA) published a final order entitled “Effective Date of Requirement for Premarket Approval for Automated External Defibrillator Systems” in the Federal Register (80 FR 5674) effective on February 3, 2015. AED systems consist of an AED and those AED accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., pad electrodes, batteries, adapters, and hardware keys for pediatric use) (“necessary AED accessories”). The final order required the submission, by May 4, 2015, of a premarket approval (“PMA”) application for AEDs and necessary AED accessories that were in commercial distribution before May 28, 1976, or that were, by May 4, 2015, found to be substantially equivalent to any AED or necessary AED accessory that was in commercial distribution before May 28, 1976.\n\nAt the time of the final order, FDA announced its intent not to enforce compliance with the 90 day deadline to submit a PMA for then currently marketed AEDs for 15 months after the deadline, provided certain qualifications were met. FDA also stated that it did not intend to enforce compliance with the PMA submission requirement for necessary AED accessories for 60 months following the February 3, 2015, effective date of the final order, which was February 3, 2020.\n\nOn October 28, 2020, FDA issued the guidance document, “Necessary Automated External Defibrillator Accessories: Policy Regarding Compliance Date,” to revise its compliance policy regarding the deadline for filing PMA applications for previously cleared necessary AED accessories. The purpose of this guidance was, in part, to present a less burdensome policy consistent with the public health given the challenges related to the Coronavirus Disease 2019 (COVID-19) pandemic. The guidance outlined that FDA did not intend to enforce compliance with the premarket approval requirements under section 515 of the Act for necessary AED accessories for AED systems, classified under 21 CFR 870.5310 and product codes MKJ and NSA, until February 3, 2022.\n\nOur inspection revealed that your firm manufactures batteries that are used with AED systems, specifically part number AM9146-2 intended to be used with the Cardiac Science Powerheart G3 and G3 Plus devices, part number AM5070 intended to be used with the Philips HeartStart FRx, OnSite, and Home devices, and part number AM1000 intended to be used with the Physio-Control LifePak 1000 device.1 FDA has determined that your firm has not submitted a PMA by the February 3, 2022, compliance date for these devices and that your firm has continued to manufacture and distribute these devices after the compliance date.\n\nConsequently, your devices are adulterated under section 501(f)(1)(A) of the Act, 21 U.S.C. § 351(f)(1)(A), because they have been required by an order issued under section 515(b) of the Act, 21 U.S.C. § 360e(b), to have an approval under such section of an application for premarket approval, are not exempt from section 515 under section 520(g) of the Act, 21 U.S.C. § 360j(g), and your firm has not filed an application for premarket approval by the compliance date cited above.\n\nThe kind of information that your firm needs to submit in order to obtain approval for the devices is available through the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether your products may be legally marketed.\n\nFDA requests that your firm cease activities that result in the adulteration of necessary AED accessories.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Gina Brackett, Director of Compliance Branch, at oradevices1firmresponse@fda.hhs.gov. Refer to CMS # 681557 when replying. If you have any questions about the contents of this letter, please contact Compliance Officer, Karen Archdeacon at 781-587-7491 or at karen.archdeacon@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health Division 1\n\nORA Division Director\n\nand\n\n\u002FS\u002F\n\nBram Zuckerman\n\nDirector Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_____________________\n\n1 Our inspection also revealed that your firm has manufactured other batteries that are used with AED systems, including part number 5L318, 6L785, 5L500, and AM9141. These batteries are intended to be used with devices that have been discontinued. Your firm has continued to manufacture and distribute these devices after the February 3, 2022 compliance date.","AMCO International Manufacturing & Design, Inc.","amco-international-manufacturing-design-inc-681557-06252024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famco-international-manufacturing-design-inc-681557-06252024","2026-10-26T08:07:54.465747+00:00","2024-07-30","681557","Adam Milewski","2026-08-19T23:55:19.634+00:00","United Parcel Service","2024-06-25",4,{"510k":98,"classification":99,"enforcement":100,"event":101,"event_backfill":102,"pma":103,"warning_letter":104},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]